Table 2.
Results of HTS of CSC with 19 FDA-approved oncology drugs
| NSC | Name | % growth | SD (%) | p-value | p-adj | GI50OVCAR3 (−log10) |
|---|---|---|---|---|---|---|
| 3053 |
Dactinomycin |
8.4 |
3.9 |
1.38E-08 |
1.07E-05 |
8.54 |
| 24559 |
Plicamycin |
10.8 |
3.6 |
9.91E-11 |
7.86E-08 |
7.35 |
| 67574 |
Vincristine |
27.0 |
6.0 |
1.21E-06 |
8.74E-04 |
7.68 |
| 14229 |
Mepacrine |
37.6 |
6.1 |
9.93E-08 |
7.56E-05 |
5.55 |
| 49842 |
Vinblastine |
49.1 |
10.6 |
2.34E-05 |
1.56E-02 |
9.71 |
| 125066 |
Bleomycin |
53.0 |
10.2 |
1.10E-05 |
7.54E-03 |
5.28 |
| 63878 |
Cytarabine |
76.6 |
11.0 |
1.04E-02 |
1 |
5.00 |
| 105014 |
Cladribine |
82.7 |
17.0 |
7.13E-02 |
1 |
4.59 |
| 755 |
Mercaptopurine |
95.2 |
8.4 |
2.83E-01 |
1 |
5.94 |
| 740 |
Methotrexate |
96.7 |
30.8 |
8.38E-01 |
1 |
6.69 |
| 226080 |
Rapamycin |
97.0 |
20.9 |
7.93E-01 |
1 |
8.17 |
| 296961 |
Amifostine |
99.4 |
12.0 |
9.18E-01 |
1 |
3.13 |
| 85998 |
Streptozocin |
103.7 |
28.9 |
8.10E-01 |
1 |
3.14 |
| 32065 |
Hydroxyurea |
107.4 |
14.8 |
2.38E-01 |
1 |
2.92 |
| 180973 |
Tamoxifen |
115.1 |
14.3 |
4.45E-02 |
1 |
5.23 |
| 750 |
Busulfan |
120.6 |
15.9 |
3.65E-02 |
1 |
3.60 |
| 38721 |
Mitotane |
128.2 |
47.6 |
2.68E-01 |
1 |
4.73 |
| 9706 |
Triethylenemelamine |
128.9 |
82.5 |
5.26E-01 |
1 |
4.74 |
| 45388 | Dacarbazine | 164.3 | 14.2 | 4.46E-04 | 2.68E-01 | 4.25 |